A Phase 2 interventional study of Desloratadine plus cilostazol and dipyridamole and Desloratadine in Chronic Urticaria, sponsored by Chulalongkorn University. Active, not recruiting at 1 site in Thailand. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-02-21.
Sponsored by Chulalongkorn University · Phase 2, Interventional, and Treatment
This study compares the combination of antiplatelets and antihistamine versus antihistamine alone for the treatment of chronic spontaneous urticaria
This study is a randomized control trial comparing the effectiveness of the combination of antiplatelets and antihistamine and antihistamine alone for the treatment of chronic spontaneous urticaria
237 studies on the registry are indexed under Urticaria; 26 are open to participants now.
This study's planned enrollment of 12 is below the median of 61 across 174 interventional studies indexed under Urticaria.
Browse Urticaria studies →Chulalongkorn University is the lead sponsor of 312 studies on the registry; 59 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Chronic spontaneous urticaria
D-dimer levels over 500 ng/ml
Not respond to a conventional dose of antihistamine
Exclusion Criteria:
Are taking aspirin
Have bleeding tendency
Have concurrent severe medical illnesses
-
Oral desloratadine 20 mg/day (antihistamine) for 4 weeks
Drug: Desloratadine
Oral desloratadine 20 mg/day (antihistamine) in conjunction with cilostazol 150 mg/day and dipyridamole 50 mg/day (antiplatelets) for 4 weeks
Drug: Desloratadine plus cilostazol and dipyridamole · Drug: Desloratadine
Desloratadine 20 mg/day plus cilostazol 150 mg/day and dipyridamole 50 mg/day
Also known as: Antihistamine plus antiplatelets
Desloratadine 20 mg/day
Also known as: Antihistamine alone
Weekly urticaria activity score
Urticaria activity score over 7 days (UAS7): scores 0-42 from mild to severe
Time frame: 4 weeks
D-dimer levels
D-dimer levels
Time frame: 4 weeks
Plan to share: No
No publications or documents are linked to this record.
This study is active, not recruiting, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chulalongkorn University